{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:17:25Z","timestamp":1791605845044,"version":"4.3.4"},"reference-count":63,"publisher":"American Diabetes Association","issue":"4","license":[{"start":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T00:00:00Z","timestamp":1553040000000},"content-version":"vor","delay-in-days":57,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"DOI":"10.13039\/501100001030","name":"National Heart Foundation of Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,4,1]]},"abstract":"<jats:p>Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist, and phentermine, a psychostimulant structurally related to amphetamine, are drugs approved for the treatment of obesity and hyperphagia. There is significant interest in combination use of liraglutide and phentermine for weight loss; however, both drugs have been reported to induce systemic hemodynamic changes, and as such the therapeutic window for this drug combination needs to be determined. To understand their impact on metabolic and cardiovascular physiology, we tested the effects of these drugs alone and in combination for 21 days in lean and obese male mice. The combination of liraglutide and phentermine, at 100 \u03bcg\/kg\/day and 10 mg\/kg\/day, respectively, produced the largest reduction in body weight in both lean and diet-induced obese (DIO) mice, when compared with both vehicle and monotherapy-treated mice. In lean mice, combination treatment at the aforementioned doses significantly increased heart rate and reduced blood pressure, whereas in DIO mice, combination therapy induced a transient increase in heart rate and decreased blood pressure. These studies demonstrate that in obese mice, the combination of liraglutide and phentermine may reduce body weight but only induce modest improvements in cardiovascular functions. Conversely, in lean mice, the additional weight loss from combination therapy does not improve cardiovascular parameters.<\/jats:p>","DOI":"10.2337\/db18-1149","type":"journal-article","created":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T20:27:54Z","timestamp":1548275274000},"page":"683-695","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":12,"title":["Determining the Effects of Combined Liraglutide and Phentermine on Metabolic Parameters, Blood Pressure, and Heart Rate in Lean and Obese Male Mice"],"prefix":"10.2337","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1590-6190","authenticated-orcid":false,"given":"Stephanie E.","family":"Simonds","sequence":"first","affiliation":[{"name":"Metabolic Disease and Obesity Program, Monash Biomedicine Discovery Institute, and Department of Physiology, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack T.","family":"Pryor","sequence":"additional","affiliation":[{"name":"Metabolic Disease and Obesity Program, Monash Biomedicine Discovery Institute, and Department of Physiology, Monash University, Melbourne, Victoria, Australia"},{"name":"Woodrudge LTD, London, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank H.","family":"Koegler","sequence":"additional","affiliation":[{"name":"Novo Nordisk Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberte S.","family":"Buch-Rasmussen","sequence":"additional","affiliation":[{"name":"Metabolic Disease and Obesity Program, Monash Biomedicine Discovery Institute, and Department of Physiology, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E.","family":"Kelly","sequence":"additional","affiliation":[{"name":"Metabolic Disease and Obesity Program, Monash Biomedicine Discovery Institute, and Department of Physiology, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Grove","sequence":"additional","affiliation":[{"name":"Novo Nordisk Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7811-134X","authenticated-orcid":false,"given":"Michael A.","family":"Cowley","sequence":"additional","affiliation":[{"name":"Metabolic Disease and Obesity Program, Monash Biomedicine Discovery Institute, and Department of Physiology, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2019,1,22]]},"reference":[{"key":"2022031303391882400_B1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1614362","article-title":"Health effects of overweight and obesity in 195 countries over 25 years","volume":"377","author":"Afshin","year":"2017","journal-title":"N Engl J Med"},{"key":"2022031303391882400_B2","first-page":"177","article-title":"Leptin increasing sympathetic nerve outflow in obesity: a cure for obesity or a potential contributor to metabolic syndrome","volume-title":"Adipocyte","author":"Simonds","year":"2012"},{"key":"2022031303391882400_B3","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.orcp.2017.07.002","article-title":"Current and emerging pharmacotherapies for obesity in Australia","volume":"11","author":"Hocking","year":"2017","journal-title":"Obes Res Clin Pract"},{"key":"2022031303391882400_B4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1463-1326.2012.01557.x","article-title":"Liraglutide: short-lived effect on gastric emptying -- long lasting effects on body weight","volume":"14","author":"Jelsing","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"2022031303391882400_B5","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.2337\/diabetes.50.11.2530","article-title":"Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats","volume":"50","author":"Larsen","year":"2001","journal-title":"Diabetes"},{"key":"2022031303391882400_B6","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/oby.2007.204","article-title":"Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs","volume":"15","author":"Raun","year":"2007","journal-title":"Obesity (Silver Spring)"},{"key":"2022031303391882400_B7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2337\/db06-0565","article-title":"Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not","volume":"56","author":"Raun","year":"2007","journal-title":"Diabetes"},{"key":"2022031303391882400_B8","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.neuroimage.2006.12.035","article-title":"Postprandial glucagon-like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans","volume":"35","author":"Pannacciulli","year":"2007","journal-title":"Neuroimage"},{"key":"2022031303391882400_B9","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s00125-016-3874-y","article-title":"GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial","volume":"59","author":"Farr","year":"2016","journal-title":"Diabetologia"},{"key":"2022031303391882400_B10","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2337\/dc15-0772","article-title":"Liraglutide reduces CNS activation in response to visual food cues only after short-term treatment in patients with type 2 diabetes","volume":"39","author":"Ten Kulve","year":"2016","journal-title":"Diabetes Care"},{"key":"2022031303391882400_B11","first-page":"R848","article-title":"Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats","volume":"271","author":"Tang-Christensen","year":"1996","journal-title":"Am J Physiol"},{"key":"2022031303391882400_B12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/379069a0","article-title":"A role for glucagon-like peptide-1 in the central regulation of feeding","volume":"379","author":"Turton","year":"1996","journal-title":"Nature"},{"key":"2022031303391882400_B13","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1172\/JCI990","article-title":"Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans","volume":"101","author":"Flint","year":"1998","journal-title":"J Clin Invest"},{"key":"2022031303391882400_B14","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1210\/en.2008-1221","article-title":"Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms","volume":"150","author":"R\u00fcttimann","year":"2009","journal-title":"Endocrinology"},{"key":"2022031303391882400_B15","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1523\/JNEUROSCI.2212-10.2011","article-title":"Hyperphagia and increased fat accumulation in two models of chronic CNS glucagon-like peptide-1 loss of function","volume":"31","author":"Barrera","year":"2011","journal-title":"J Neurosci"},{"key":"2022031303391882400_B16","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/nm1196-1254","article-title":"Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene","volume":"2","author":"Scrocchi","year":"1996","journal-title":"Nat Med"},{"key":"2022031303391882400_B17","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.2337\/db09-1414","article-title":"The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action","volume":"59","author":"Hare","year":"2010","journal-title":"Diabetes"},{"key":"2022031303391882400_B18","first-page":"E981","article-title":"Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans","volume":"273","author":"Nauck","year":"1997","journal-title":"Am J Physiol"},{"key":"2022031303391882400_B19","first-page":"4382","article-title":"A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans","volume":"86","author":"Verdich","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031303391882400_B20","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.2337\/db10-0474","article-title":"Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans","volume":"60","author":"Nauck","year":"2011","journal-title":"Diabetes"},{"key":"2022031303391882400_B21","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1172\/JCI72434","article-title":"Neuronal GLP1R mediates liraglutide\u2019s anorectic but not glucose-lowering effect","volume":"124","author":"Sisley","year":"2014","journal-title":"J Clin Invest"},{"key":"2022031303391882400_B22","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/ijo.2013.162","article-title":"Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults","volume":"38","author":"van Can","year":"2014","journal-title":"Int J Obes"},{"key":"2022031303391882400_B23","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study","volume":"374","author":"Astrup","year":"2009","journal-title":"Lancet"},{"key":"2022031303391882400_B24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1172\/JCI0215595","article-title":"Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons","volume":"110","author":"Yamamoto","year":"2002","journal-title":"J Clin Invest"},{"key":"2022031303391882400_B25","first-page":"A285","article-title":"No impairment of hypoglycaemia counterregulation via glucagon with the long-acting GLP-1 derivative, NN2211, in subjects with type 2-diabetes","volume":"46","author":"Nauck","year":"2003","journal-title":"Diabetologia"},{"key":"2022031303391882400_B26","first-page":"A128","article-title":"No impairment of hypoglycemia counterregulation via glucagon with NN2211, a GLP-1 derivative, in subjects with type 2-diabetes","volume":"52","author":"Nauck","year":"2003","journal-title":"Diabetes"},{"key":"2022031303391882400_B27","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nm.3128","article-title":"GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure","volume":"19","author":"Kim","year":"2013","journal-title":"Nat Med"},{"key":"2022031303391882400_B28","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2337\/dc14-1958","article-title":"Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes","volume":"38","author":"Lovshin","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031303391882400_B29","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2022031303391882400_B30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5625\/lar.2014.30.2.73","article-title":"Effects of anti-obesity drugs, phentermine and mahuang, on the behavioral patterns in Sprague-Dawley rat model","volume":"30","author":"Go","year":"2014","journal-title":"Lab Anim Res"},{"key":"2022031303391882400_B31","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1001\/archinte.1984.00350180055008","article-title":"A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination","volume":"144","author":"Weintraub","year":"1984","journal-title":"Arch Intern Med"},{"key":"2022031303391882400_B32","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1001\/archinte.163.9.1046","article-title":"National trends in antiobesity medication use","volume":"163","author":"Stafford","year":"2003","journal-title":"Arch Intern Med"},{"key":"2022031303391882400_B33","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1038\/oby.2009.69","article-title":"How physician obesity specialists use drugs to treat obesity","volume":"17","author":"Hendricks","year":"2009","journal-title":"Obesity (Silver Spring)"},{"key":"2022031303391882400_B34","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1038\/oby.2011.94","article-title":"Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity","volume":"19","author":"Hendricks","year":"2011","journal-title":"Obesity (Silver Spring)"},{"key":"2022031303391882400_B35","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/adc.41.217.309","article-title":"Obesity in childhood. A controlled trial of anorectic drugs","volume":"41","author":"Lorber","year":"1966","journal-title":"Arch Dis Child"},{"key":"2022031303391882400_B36","first-page":"591","article-title":"Plasma phentermine levels, weight loss and side-effects","volume":"7","author":"Douglas","year":"1983","journal-title":"Int J Obes"},{"key":"2022031303391882400_B37","first-page":"300","article-title":"A comparative study of phentermine and diethylpropion in the treatment of obese patients in general practice","volume":"3","author":"Vall\u00e9-Jones","year":"1983","journal-title":"Pharmatherapeutica"},{"key":"2022031303391882400_B38","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/oby.20584","article-title":"Evaluation of phentermine and topiramate versus phentermine\/topiramate extended-release in obese adults","volume":"21","author":"Aronne","year":"2013","journal-title":"Obesity (Silver Spring)"},{"key":"2022031303391882400_B39","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine","volume":"337","author":"Connolly","year":"1997","journal-title":"N Engl J Med"},{"key":"2022031303391882400_B40","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.cell.2014.10.058","article-title":"Leptin mediates the increase in blood pressure associated with obesity","volume":"159","author":"Simonds","year":"2014","journal-title":"Cell"},{"key":"2022031303391882400_B41","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.cmet.2011.09.011","article-title":"Elevated hypothalamic TCPTP in obesity contributes to cellular leptin resistance","volume":"14","author":"Loh","year":"2011","journal-title":"Cell Metab"},{"key":"2022031303391882400_B42","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0091-7435(87)90087-9","article-title":"Incidence and precursors of hypertension in young adults: the Framingham Offspring study","volume":"16","author":"Garrison","year":"1987","journal-title":"Prev Med"},{"key":"2022031303391882400_B43","doi-asserted-by":"crossref","first-page":"e0001986","DOI":"10.1136\/bmjopen-2012-001986","article-title":"Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis","volume":"3","author":"Robinson","year":"2013","journal-title":"BMJ Open"},{"key":"2022031303391882400_B44","first-page":"pii:764584","article-title":"Experience (mostly negative) with the use of sympathomimetic agents for weight loss","volume-title":"J Obes","author":"Inchiosa","year":"2011"},{"key":"2022031303391882400_B45","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1210\/jc.2014-3415","article-title":"Pharmacological management of obesity: an Endocrine Society clinical practice guideline","volume":"100","author":"Apovian","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031303391882400_B46","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1056\/NEJM199708283370904","article-title":"Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine","volume":"337","author":"Mark","year":"1997","journal-title":"N Engl J Med"},{"key":"2022031303391882400_B47"},{"key":"2022031303391882400_B48","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1097\/HJH.0000000000000145","article-title":"Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity","volume":"32","author":"Jordan","year":"2014","journal-title":"J Hypertens"},{"key":"2022031303391882400_B49","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"key":"2022031303391882400_B50","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/aps.2011.168","article-title":"Effects of liraglutide and sibutramine on food intake, palatability, body weight and glucose tolerance in the gubra DIO-rats","volume":"33","author":"Hansen","year":"2012","journal-title":"Acta Pharmacol Sin"},{"key":"2022031303391882400_B51","doi-asserted-by":"crossref","first-page":"e0153151","DOI":"10.1371\/journal.pone.0153151","article-title":"Weight and glucose reduction observed with a combination of nutritional agents in rodent models does not translate to humans in a randomized clinical trial with healthy volunteers and subjects with type 2 diabetes","volume":"11","author":"Hodge","year":"2016","journal-title":"PLoS One"},{"key":"2022031303391882400_B52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2014.04.004","article-title":"Naltrexone\/bupropion for obesity: an investigational combination pharmacotherapy for weight loss","volume":"84","author":"Billes","year":"2014","journal-title":"Pharmacol Res"},{"key":"2022031303391882400_B53","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1007\/s00125-015-3651-3","article-title":"Contribution of brown adipose tissue activity to the control of energy balance by GLP-1 receptor signalling in mice","volume":"58","author":"Heppner","year":"2015","journal-title":"Diabetologia"},{"key":"2022031303391882400_B54","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.2337\/db14-0302","article-title":"GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK","volume":"63","author":"Beiroa","year":"2014","journal-title":"Diabetes"},{"key":"2022031303391882400_B55","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/(SICI)1098-2396(200005)36:2<102::AID-SYN3>3.0.CO;2-#","article-title":"Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: therapeutic implications","volume":"36","author":"Baumann","year":"2000","journal-title":"Synapse"},{"key":"2022031303391882400_B56","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s002130050598","article-title":"Efficacy of administration of dexfenfluramine and phentermine, alone and in combination, on ingestive behavior and body weight in rats","volume":"137","author":"Roth","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"key":"2022031303391882400_B57","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/ijo.2008.91","article-title":"Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats","volume":"32","author":"Roth","year":"2008","journal-title":"Int J Obes"},{"key":"2022031303391882400_B58","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.physbeh.2012.03.014","article-title":"Exendin-4 decreases amphetamine-induced locomotor activity","volume":"106","author":"Erreger","year":"2012","journal-title":"Physiol Behav"},{"key":"2022031303391882400_B59","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.diabres.2015.07.015","article-title":"Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"110","author":"Sun","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"key":"2022031303391882400_B60","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2337\/dc16-1580","article-title":"Effects of liraglutide on heart rate and heart rate variability: a randomized, double-blind, placebo-controlled crossover study","volume":"40","author":"Kumarathurai","year":"2017","journal-title":"Diabetes Care"},{"key":"2022031303391882400_B61","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12902-015-0074-6","article-title":"An association between liraglutide treatment and reduction in excessive daytime sleepiness in obese subjects with type 2 diabetes","volume":"15","author":"Gomez-Peralta","year":"2015","journal-title":"BMC Endocr Disord"},{"key":"2022031303391882400_B62","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1161\/01.CIR.96.10.3423","article-title":"Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects","volume":"96","author":"Vaz","year":"1997","journal-title":"Circulation"},{"key":"2022031303391882400_B63","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial","volume":"40","author":"Blackman","year":"2016","journal-title":"Int J Obes"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/diabetes.diabetesjournals.org\/syndication\/doi\/10.2337\/db18-1149","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/68\/4\/683\/523518\/db181149.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/68\/4\/683\/523518\/db181149.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:37:20Z","timestamp":1667407040000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/68\/4\/683\/39785\/Determining-the-Effects-of-Combined-Liraglutide"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,22]]},"references-count":63,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,1,22]]},"published-print":{"date-parts":[[2019,4,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db18-1149","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,22]]}}}